Skip to main content

Table 1 Data on discordance of ER, PgR and HER2 status between primary and metastatic breast cancer

From: Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives

Reference

ER discordance (%)

PgR discordance (%)

HER2 discordance (%)

Lindstrom et al. [7]

32.4

40.7

14.5

Niikura et al. [8]

NR

NR

43

Curigliano et al. [9]

15

49

14

Gong et al. [10]

7

NR

NR

Amir et al. [2]

12.6

31.2

5.5

Bogina et al. [11]

6

21

1

Wilking et al. [12]

NR

NR

10

Aitken et al. [13]

28

23

9

Amir et al. [4]

16

40.4

9.6

Idirisinghe et al. [14]

16

38

5

Simmons et al. [15]

40

40

8

Liedtke et al. [16]

18

40

14

Lower et al. [17]

NR

NR

33

Broom et al. [18]

17.7

37.3

5.5

Santinelli et al. [19]

NR

NR

18.9

Tapia et al. [20]

NR

NR

8

Lower et al. [21]

30

39

NR

Carlsson et al. [22]

NR

NR

0

Edgerton et al. [23]

NR

NR

15

Gancberg et al. [24]

NR

NR

9

Simon et al. [25]

NR

NR

3

Mobbs et al. [26]

14

28

NR

Guarneri et al. [27]

22

36

16

Hoefnagel et al. [28]

10.3

30

5.2

Thompson et al. [5]

10.2

24.8

2.9

Brogi et al. [29]

16.2

20.6

5

Chang et al. [30]

25

NR

12.5

  1. ER, estrogen receptor; HER, human epidermal growth factor receptor; NR, not reported; PgR, progesterone receptor.